Patent application number | Description | Published |
20080305491 | MCM6 AND MCM7 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 12-11-2008 |
20090075300 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CERVICAL DISEASE - Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided. | 03-19-2009 |
20090148864 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CERVICAL DISEASE - Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided. | 06-11-2009 |
20090317826 | MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM2. Monoclonal antibodies having the binding characteristics of an MCM2 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM2 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM2 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM2 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 12-24-2009 |
20120015375 | MCM6 AND MCM7 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 01-19-2012 |
20130164760 | METHODS AND COMPOSITIONS FOR PREPARING SAMPLES FOR IMMUNOSTAINING - Compositions and methods for preparing a sample for immunological staining are provided. Compositions include kits comprising a first solution comprising a surfactant and a second solution comprising a chaotropic agent. Methods comprise contacting a sample, such as cells or tissues, with a first solution comprising a surfactant and then contacting the sample with a second solution comprising a chaotropic agent. The method does not require extreme heat for antigen retrieval and therefore, maintains the cellular morphology of the sample. | 06-27-2013 |
Patent application number | Description | Published |
20120064124 | MACROLIDE DOSAGE FORMS - Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile. | 03-15-2012 |
20120172787 | DRUG DELIVERY MEDICAL DEVICE - Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents. | 07-05-2012 |
20120177742 | NANOPARTICLE AND SURFACE-MODIFIED PARTICULATE COATINGS, COATED BALLOONS, AND METHODS THEREFORE - Devices, coatings, and methods therefore comprise a medical device for delivering nanoparticles of an active agent to a treatment site. A coating on the medical device comprises active agent nanoparticles, which delivers coating to the treatment site and releases active agent nanoparticles into the treatment site over at least one day. A coating may comprise a polymer, a surfactant, and the nanoparticles. The coating may be prepared by forming a nanoemulsion. A coating may comprise encapsulated active agent nanoparticles which comprise active agent nanoparticles encapsulated in a polymer. The coating may have a positive surface charge. The coating may deliver active agent nanoparticles into the treatment site over at least about one day. The coating may be formed of a surfactant and nanoparticles mixture. The active agent nanoparticles may be deposited on the medical device using electrostatic capture. | 07-12-2012 |
20120323311 | STENTS HAVING CONTROLLED ELUTION - Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form. | 12-20-2012 |
20130172853 | DRUG DELIVERY MEDICAL DEVICE - Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents. | 07-04-2013 |
20140257465 | STENTS HAVING CONTROLLED ELUTION - Provided herein is a device comprising a stent and a coating on the stent; wherein the coating comprises at least one polymer and at least one active agent; wherein at least part of the active agent is in crystalline form. | 09-11-2014 |
20140277401 | BIOABSORBABLE BIOMEDICAL IMPLANTS - A bioabsorbable biomedical implant is disclosed. The implant includes a tubular scaffold comprising a plurality of interconnected polymer struts. The interconnected polymer struts defines a plurality of deformable cells. The polymer struts have an average thickness of no more than 120 μm. Methods for making the bioabsorbable biomedical implant, including the methods for making the polymer materials for the tubular scaffold, are also disclosed. | 09-18-2014 |
20140350522 | DRUG DELIVERY MEDICAL DEVICE - Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents. | 11-27-2014 |
20140371717 | DRUG DELIVERY MEDICAL DEVICE - A medical device that releases a pharmaceutical agent to a target site is disclosed. The medical device includes a balloon, and a coating on at least a portion of the balloon. Each particle of the particles of the pharmaceutical agent is at least partially encapsulated in a polymer layer. The method includes the steps of providing a device including a balloon, and a coating on at least a portion of the balloon, the coating including particles of a pharmaceutical agent, and each particle of the pharmaceutical agent is at least partially encapsulated in a polymer layer; positioning the device to allow the balloon to reach the target site; and inflating the balloon of the device. | 12-18-2014 |
20150087671 | LOW BURST SUSTAINED RELEASE LIPOPHILIC AND BIOLOGIC AGENT COMPOSITIONS - A drug delivery composition including a lipophilic agent or a biologic agent and a polymer wherein the lipophilic agent exhibits sustained release and wherein there is less than 35% agent release within the first hour of elution. A drug delivery composition including a lipophilic agent or a biologic agent and a polymer wherein the elution profile is substantially linear, and wherein there is less than 35% agent release within the first hour of elution. The lipophilic agent may be crystalline and the biologic agent may be in active form. | 03-26-2015 |
20150134047 | SAFE DRUG ELUTING STENT WITH ABSORBABLE COATING - Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form. | 05-14-2015 |
20150250926 | DRUG DELIVERY MEDICAL DEVICE - A medical device that releases a pharmaceutical agent to a target site is disclosed. The medical device includes a balloon, and a coating on at least a portion of the balloon. The coating includes particles of a pharmaceutical agent. Each particle of the particles of the pharmaceutical agent is at least partially encapsulated in a polymer material. A method of releasing a pharmaceutical agent at a target site is also disclosed. The method includes the steps of providing a device including a balloon, and a coating on at least a portion of the balloon, the coating including particles of a pharmaceutical agent, and each particle of the pharmaceutical agent is at least partially encapsulated in a polymer material; positioning the device to allow the balloon to reach the target site; and inflating the balloon of the device. | 09-10-2015 |
20150320914 | STENTS HAVING BIODEGRADABLE LAYERS - Provided herein is a coated coronary stent, comprising: a. stent framework; b. a plurality of layers deposited on said stent framework to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form. | 11-12-2015 |
20160095726 | STENTS HAVING CONTROLLED ELUTION - Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form. | 04-07-2016 |
20160101220 | COATINGS CONTAINING MULTIPLE DRUGS - A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents. | 04-14-2016 |
Patent application number | Description | Published |
20090062909 | STENT WITH POLYMER COATING CONTAINING AMORPHOUS RAPAMYCIN - A coated coronary stent, comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating. | 03-05-2009 |
20090123515 | POLYMER COATINGS CONTAINING DRUG POWDER OF CONTROLLED MORPHOLOGY - A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent. | 05-14-2009 |
20090186069 | Coatings Containing Multiple Drugs - A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents. | 07-23-2009 |
20110159069 | Medical Implants and Methods of Making Medical Implants - A medical implant device having a substrate with an oxidized surface and a silane derivative coating covalently bonded to the oxidized surface. A bioactive agent is covalently bonded to the silane derivative coating. An implantable stent device including a stent core having an oxidized surface with a layer of silane derivative covalently bonded thereto. A spacer layer comprising polyethylene glycol (PEG) is covalently bonded to the layer of silane derivative and a protein is covalently bonded to the PEG. A method of making a medical implant device including providing a substrate having a surface, oxidizing the surface and reacting with derivitized silane to form a silane coating covalently bonded to the surface. A bioactive agent is then covalently bonded to the silane coating. In particular instances, an additional coating of bio-absorbable polymer and/or pharmaceutical agent is deposited over the bioactive agent. | 06-30-2011 |
20130006351 | POLYMER COATINGS CONTAINING DRUG POWDER OF CONTROLLED MORPHOLOGY - A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent. | 01-03-2013 |
20150025620 | POLYMER COATINGS CONTAINING DRUG POWDER OF CONTROLLED MORPHOLOGY - A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent. | 01-22-2015 |
20150112424 | COATINGS CONTAINING MULTIPLE DRUGS - A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents. | 04-23-2015 |
Patent application number | Description | Published |
20120137879 | HIGH PRESSURE LIQUID DEGASSING MEMBRANE CONTACTORS AND METHODS OF MANUFACTURING AND USE - In accordance with at least selected embodiments of the present invention, an improved liquid degassing membrane contactor or module includes a high pressure housing and at least one degassing cartridge therein. It may be preferred that the high pressure housing is a standard, ASME certified, reverse osmosis (RO) or water purification pressure housing or vessel (made of, for example, polypropylene, polycarbonate, stainless steel, corrosion resistant filament wound fiberglass reinforced epoxy tubing, with pressure ratings of for example, 150, 250, 300, 400, or 600 psi, and with, for example 4 or 6 ports, and an end cap at each end) and that the degassing cartridge is a self-contained, hollow-fiber membrane cartridge adapted to fit in the RO high pressure housing. | 06-07-2012 |
20120168379 | WAFER-SHAPED HOLLOW FIBER MODULE FOR IN-LINE USE IN A PIPING SYSTEM - A wafer-shaped hollow fiber module adapted for in-line use in a piping system. The piping system may include two standard bolted flange connections, and at least one wafer-shaped hollow fiber module sealed between the two standard bolted flange connections. The wafer shaped hollow fiber module includes: a cylindrical housing having an open end and a closed end having a first sealing surface and an inlet port; at least one side port through the cylindrical housing; an end cap united to the open end having a second sealing surface and an outlet port. | 07-05-2012 |
20120247337 | LIQUID DEGASSING MEMBRANE CONTACTORS, COMPONENTS, SYSTEMS AND RELATED METHODS - The present invention is directed to contactors, modules, components, systems, and/or methods of manufacture, and/or methods of use including degassing liquids. The contactor or module is integrally potted, has planar, disc shaped end caps, and a cylindrical housing or shell receiving and supporting a membrane structure. Each of the planar disc shaped end caps has a central opening therein adapted to receive a liquid end port or nozzle and is held in place in the housing or shell by at least one retaining element. The integrally potted membrane structure is preferably potted in place in the housing or shell by an inverted potting process involving the use of a removable plunger or plug to recess the potting. | 10-04-2012 |
20120304862 | FLAT PANEL CONTACTORS AND METHODS - Porous membrane contactors and/or their methods of manufacture and/or use are provided. In at least selected embodiments, the present invention is directed to flat panel hollow fiber or flat sheet membrane contactors and/or their methods of manufacture and/or use. In at least certain particular embodiments, the present invention is directed to hollow fiber array flat panel contactors, contactor systems, and/or their methods of manufacture and/or use. In at least particular possibly preferred embodiments, the contactor is adapted for placement in an air duct (such as an HVAC ductwork) and has a rectangular frame or housing enclosing at least one wound hollow fiber array or membrane bundle. | 12-06-2012 |
20130043177 | WAFER-SHAPED HOLLOW FIBER MODULE FOR IN-LINE USE IN A PIPING SYSTEM - A wafer-shaped hollow fiber module adapted for in-line use in a piping system. The piping system may include two standard bolted flange connections, and at least one wafer-shaped hollow fiber module sealed between the two standard bolted flange connections. The wafer shaped hollow fiber module includes: a cylindrical housing having an open end and a closed end having a first sealing surface and an inlet port; at least one side port through the cylindrical housing; an end cap united to the open end having a second sealing surface and an outlet port. | 02-21-2013 |
20130247760 | LIQUID DEGASSING MEMBRANE CONTACTORS, COMPONENTS, SYSTEMS AND RELATED METHODS - In at least certain embodiments, the present invention is directed to contactors, modules, components, systems, and/or methods of manufacture, and/or methods of use including degassing liquids. In at least particular possibly preferred embodiments, the contactor or module is integrally potted, has planar, disc shaped end caps, and a cylindrical housing or shell receiving and supporting a membrane structure. In at least particular possibly preferred embodiments, each of the planar disc shaped end caps has a central opening therein adapted to receive a liquid end port or nozzle, another opening therein adapted to receive a gas end port or threaded pipe, and is held in place in the housing or shell by at least one retaining element such as a retaining or locking ring. In at least particular possibly preferred embodiments, the integrally potted membrane structure is potted in place in the housing or shell by an inverted potting process involving the use of a removable plunger or plug to recess the potting. | 09-26-2013 |
20130327219 | HIGH PRESSURE LIQUID DEGASSING MEMBRANE CONTACTORS AND METHODS OF MANUFACTURING AND USE - In accordance with at least selected embodiments of the present invention, an improved liquid degassing membrane contactor or module includes a high pressure housing and at least one degassing cartridge therein. It may be preferred that the high pressure housing is a standard, ASME certified, reverse osmosis (RO) or water purification pressure housing or vessel (made of, for example, polypropylene, polycarbonate, stainless steel, corrosion resistant filament wound fiberglass reinforced epoxy tubing, with pressure ratings of, for example, 150, 250, 300, 400, or 600 psi, and with, for example 4 or 6 ports, and an end cap at each end) and that the degassing cartridge is a self-contained, hollow-fiber membrane cartridge adapted to fit in the RO high pressure housing. | 12-12-2013 |
20140216258 | CONTACTORS, CARTRIDGES, COMPONENTS, SYSTEMS, AND RELATED METHODS - The instant application relates to a high pressure spiral-type hollow fiber membrane fabric-containing module or contactor, comprising: a high pressure module housing or vessel; a pair of end caps; liquid end ports and at least one gas port; and at least one membrane cartridge, wherein each module or contactor has one or more shims, spacers, protrusions, and/or the like on a cartridge shell exterior, on a module housing interior, on the cartridge shell exterior and on the module housing interior, and/or between the shell and the housing. | 08-07-2014 |
20140263061 | MEMBRANE CONTACTORS AND SYSTEMS FOR MEMBRANE DISTILLATION OR AMMONIA REMOVAL AND RELATED METHODS - New, improved, or modified membrane contactors, modules, systems, and/or methods for membrane distillation and/or ammonia removal, and/or methods of manufacture, use, and/or the like. In accordance with at least selected embodiments, particular possibly preferred membrane contactors, modules, systems, and/or methods for membrane distillation and/or ammonia removal, and/or to particular possibly preferred membrane contactors, modules, systems, and/or methods for membrane distillation and/or ammonia removal, involving membrane contactors adapted for membrane distillation, for ammonia removal, or for both membrane distillation and for ammonia removal, as well as for other membrane contactor systems, methods or processes such as degassing, gasifying, separation, filtration, and/or the like. | 09-18-2014 |
20150053083 | MULTI-CARTRIDGE MEMBRANE CONTACTORS, MODULES, SYSTEMS, AND RELATED METHODS - A multi-cartridge membrane contactor that can be used for many purposes, including, but not limited to, being a multi-cartridge degassing module. In accordance with at least particular certain embodiments, the module includes a plurality of hollow-fiber cartridges placed in a radial pattern around a central cartridge within a single larger vessel. For example, there may be two radial sets of cartridges placed in series at each of the radial positions. | 02-26-2015 |
Patent application number | Description | Published |
20090091186 | SYSTEM AND METHOD FOR MULTIPLE SENSE POINT VOLTAGE REGULATION - The present invention is a system and method for sensing the voltage at multiple sense points. The present invention acquires optimal feedback from a plurality of sources including those integrated on the same motherboard, for populated or unpopulated connectors and for adapter cards plugged into the connectors, for the purpose of controlling the voltage regulator output. The voltage regulator, connected to a logic system, provides voltage to those connectors needing the voltage. | 04-09-2009 |
20090164846 | Fault Injection In Dynamic Random Access Memory Modules For Performing Built-In Self-Tests - Fault injection in dynamic random access memory (‘DRAM’) modules for performing built-in self-tests (‘BISTs’) including establishing, in the mode registers of the DRAM modules by the memory controller through the shared address bus, an injection of a fault into one or more signal lines of a DRAM module, the fault characterized by a fault type; writing data by the memory controller through a data bus to the DRAM modules, the data identifying a particular DRAM module; and responsive to receiving the data, injecting, by the particular DRAM module, the fault characterized by the fault type into the one or more signal lines of the particular DRAM module. | 06-25-2009 |
20110066903 | DYNAMIC RANDOM ACCESS MEMORY HAVING INTERNAL BUILT-IN SELF-TEST WITH INITIALIZATION - A method for self-contained testing within a DRAM comprises the DRAM receiving an instruction from an external processor to test a memory core on the DRAM, and the DRAM self-testing the memory core with one or more BIST pattern stored in a multipurpose register on the DRAM. Optionally, the step of self-testing may include writing the BIST pattern into all locations of the memory core, reading each location of the memory core, and comparing the content read from each location of the memory core with the BIST pattern, wherein a negative comparison indicates a failure has occurred. In a further option, the method may further comprise, after testing the DRAM, initializing the DRAM with an INIT pattern stored in the multipurpose register on the DRAM. | 03-17-2011 |
Patent application number | Description | Published |
20120106176 | LIGHTING APPARATUS - The present disclosure relates to a lighting apparatus that includes a light engine that is coupled to a heat sink. The light engine provides a light source that generates light, and heat that is generated by the light source is dissipated, at least in part, via the heat sink. | 05-03-2012 |
20130002157 | Semiconductor Light Emitting Devices Having Selectable and/or Adjustable Color Points and Related Methods - Light emitting devices include a first string of LEDs that emit light having a color point that is within at least eight MacAdam ellipses of a first blue-shifted-yellow region on the 1931 CIE Chromaticity Diagram, a second string of LEDs that emit light having color point that is within at least eight MacAdam ellipses of a second blue-shifted-green region on the 1931 CIE Chromaticity Diagram, and a third light source that emits radiation having a dominant wavelength between 600 and 720 nm. A drive circuit supplies respective drive currents to the first string of LEDs, the second string of LEDs and the third light source, at least two of which are independently controllable. | 01-03-2013 |
20130147397 | EMERGENCY LIGHTING DEVICES WITH LED STRINGS - Emergency lighting devices and methods are disclosed. An emergency lighting device includes a first group of solid state emitters configured to emit light of a first color. The emergency lighting device also includes a second group connected in series to the first group and configured to emit a second color. The groups are configured to receive a normal operation current from an LED driver at the input end of the first group and output the normal operation current at the output end of the second group. In an emergency, the first group receives an emergency operation current from an emergency LED driver at an emergency input and outputs the emergency operation current at an emergency output located. | 06-13-2013 |
20130249374 | PASSIVE PHASE CHANGE RADIATORS FOR LED LAMPS AND FIXTURES - Heat management devices and structures are disclosed that can be used in lamps having solid state light sources such as one or more LEDs. Some lamp embodiments comprise one or more phase change radiators that utilize the latent heat of fluids to circulate and draw heat away from the LEDs and radiate the heat into the ambient, allowing for the LEDs to operate at a lower temperature. Some phase change radiators according to the present invention can comprise a main radiator body and multiple radiator coolant loops mounted to the body. The present invention relies on the circulation of heated fluid through the radiator body to radiate heat from the LEDs. The heated liquid moves away from the LEDs and is circulated back to thermal contact with the LEDs thought the coolant loops. | 09-26-2013 |
20140078715 | HIGH EFFICIENCY LIGHTING DEVICE INCLUDING ONE OR MORE SOLID STATE LIGHT EMITTERS, AND METHOD OF LIGHTING - A lighting device comprising first and second groups of solid state light emitters, that emit light having approximate dominant wavelength (in nm) of 441-448 (or 442-450, 444-455, 444-446, 442-445 or 444-452) and 555 nm to 585 nm, respectively. If the first and second groups are illuminated, a mixture of light would, in the absence of any additional light, have a color point within one or more of first, second, third, fourth and fifth areas on the 1931 CIE Chromaticity Diagram. In some embodiment, the lighting device further comprises a third group that emits light having approximate dominant wavelength (in nm) of 600-640 (or 605-610, 605-607, 600-606, 602-606 or 615-620). Also, methods of lighting. | 03-20-2014 |
20150325759 | OPTICAL ELEMENT WITH INTEGRATED INDICATOR - Solid state fixtures and packages are disclosed that include an optical element, such as an encapsulant, having an integrated indicator which indicates one or more characteristics of the package to a user, such as package orientation, polarity, chip-type, etc. The host optical element can be substantially symmetrical but for the indicator. Indicators can be additive, such as a bump, or subtractive, such as a hole. The indicator can be visible to the human eye, and/or can be machine detectable, such as by pick-and-place technology. Indicators can be formed by many processes including molding and laser ablation/imprinting, which is particularly suited for use with a hard host material. | 11-12-2015 |
20150351190 | SOLID STATE LIGHTING APPARATUSES, CIRCUITS, METHODS, AND COMPUTER PROGRAM PRODUCTS PROVIDING TARGETED SPECTRAL POWER DISTRIBUTION OUTPUT USING PULSE WIDTH MODULATION CONTROL - A solid state lighting apparatus can include a variable color input signal configured to indicate a target color of light output from the apparatus. A string current Pulse Width Modulation (PWM) controller circuit can be coupled to the variable color input signal, where the string current PWM controller circuit can be configured to generate a plurality of PWM signals having respective variable duty cycles to enable/disable respective particular string currents for respective variable times as the variable color input signal changes. | 12-03-2015 |
20160047969 | Optical Waveguide Body - An optical waveguide body includes first and second pluralities of light extraction features disposed on a first side of the waveguide body and adapted to direct light out of the waveguide body through a second side of the waveguide body opposite the first side. Each of the first plurality of light extraction features has a linear shape and each of the second plurality of light extraction features has at least one of a piecewise linear shape and a nonlinear shape. The piecewise linear shape comprises two adjacent planar surfaces with an angle therebetween of at least about 30 and at most about 180 degrees. The waveguide body further has a light coupling cavity. | 02-18-2016 |
Patent application number | Description | Published |
20120249556 | Methods, systems, and computer readable media for fast geometric sound propagation using visibility computations - Methods, systems, and computer program products for simulating sound propagation can be operable to define a sound source position within a modeled scene having a given geometry and construct a visibility tree for modeling sound propagation paths within the scene. Using from-region visibility techniques to model sound diffraction and from-point visibility technique to model specular sound reflections within the scene, the size of the visibility tree can be reduced. Using the visibility tree, an impulse response can be generated for the scene, and the impulse response can be used to simulate sound propagation in the scene. | 10-04-2012 |
20120269355 | Methods and systems for direct-to-indirect acoustic radiance transfer - Methods, systems, and computer program products for simulating propagation of sound in a static scene can be operated for pre-computing a transfer operator for simulating results of sound reflection within a modeled scene, simulating distribution of sound energy from a sound source positioned within the scene, applying the transfer operator to the distribution of sound energy from the sound source to compute simulated sound at a plurality of points within the scene, and simulating collection of sound energy from the plurality of points within the scene to a listener positioned within the scene. | 10-25-2012 |
20130010975 | Method and System for Split Client-Server Reverberation Processing - In some embodiments, a method applying reverberation to audio from at least one client of a set of clients which share a virtual environment, including by asserting position data and at least one input audio stream to a server, selecting (in the server) a reverberation filter for each input audio stream in response to the position data and generating wet audio by applying to the input audio an early reverberation part of the selected reverberation filter. Typically, a client applies a late reverberation filter to the wet audio using metadata from the server. In other embodiments, a server selects a reverberation filter for application to audio in response to position data, asserts the audio and metadata indicative of the filter, and a client applies the filter to the audio using the metadata. Other aspects are systems, servers, and client devices configured to perform any embodiment of the method. | 01-10-2013 |